You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

452 Results
Document
Guidelines and Advice
Dec 1969
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Jan 2023
Document
Document
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Relapsed Classical Hodgkin Lymphoma Post-Autologous Stem Cell Transplant or ASCT Ineligible
New Drug Funding Program
    Pembrolizumab (Adult Who Failed Prior Brentuximab Vedotin) - Relapsed Classical Hodgkin Lymphoma Post-Autologous Stem Cell Transplant or ASCT Ineligible
Jan 2023
Statistical Reports

Pages